- Home
- IVZ vs RYTM Comparison
IVZ vs RYTM Comparison
Compare IVZ & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- RYTM
- Stock Information
- Founded
- IVZ 1935
- RYTM 2008
- Country
- IVZ United States
- RYTM United States
- Employees
- IVZ N/A
- RYTM N/A
- Industry
- IVZ Investment Managers
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- IVZ Finance
- RYTM Health Care
- Exchange
- IVZ Nasdaq
- RYTM Nasdaq
- Market Cap
- IVZ 7.0B
- RYTM 5.9B
- IPO Year
- IVZ 1995
- RYTM 2017
- Fundamental
- Price
- IVZ $21.22
- RYTM $87.82
- Analyst Decision
- IVZ Hold
- RYTM Strong Buy
- Analyst Count
- IVZ 16
- RYTM 13
- Target Price
- IVZ $18.48
- RYTM $89.77
- AVG Volume (30 Days)
- IVZ 7.5M
- RYTM 1.0M
- Earning Date
- IVZ 07-22-2025
- RYTM 08-05-2025
- Dividend Yield
- IVZ 3.95%
- RYTM N/A
- EPS Growth
- IVZ N/A
- RYTM N/A
- EPS
- IVZ 1.24
- RYTM N/A
- Revenue
- IVZ $6,153,100,000.00
- RYTM $136,863,000.00
- Revenue This Year
- IVZ N/A
- RYTM $37.47
- Revenue Next Year
- IVZ $3.97
- RYTM $71.16
- P/E Ratio
- IVZ $17.17
- RYTM N/A
- Revenue Growth
- IVZ 6.02
- RYTM 48.88
- 52 Week Low
- IVZ $11.60
- RYTM $40.61
- 52 Week High
- IVZ $21.69
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- IVZ 86.51
- RYTM 71.18
- Support Level
- IVZ $16.49
- RYTM $87.86
- Resistance Level
- IVZ $17.53
- RYTM $92.14
- Average True Range (ATR)
- IVZ 0.63
- RYTM 3.57
- MACD
- IVZ 0.39
- RYTM 1.01
- Stochastic Oscillator
- IVZ 88.77
- RYTM 77.38
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.